Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2022
Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: A Prospective, Multinational, Longitudinal Cohort Study
Lancet Rheumatol. 2022. Epub ahead of print. doi: 10.1016/S2665-9913(22)00304-6
Lupus low disease activity state (LLDAS) significantly reduced the risk of mortality in patients with SLE.
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322
This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.
Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus
Nat Med. 2022;28(10):2124–2132 doi: 10.1038/s41591-022-02017-5
Data suggest that CD19 chimeric antigen receptor (CAR) T cell transfer is feasible, tolerable and highly effective in patients with SLE.
Keywords:
October 2022
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188
Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.
September 2022
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/ard-2022-222487.
Large multinational, multiethnic cohort, study highlights the importance of treating-to-target in SLE.
Keywords:
Effect and safety profile of belimumab and tacrolimus combination therapy in thirty‑three patients with systemic lupus erythematosus
Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-022-06325-6
A single-centre analysis of patients with SLE administered tacrolimus and belimumab shows this combination therapy to be well-tolerated, with a good efficacy profile and glucocorticoid-reducing effect.
Anifrolumab for Treatment of Refractory Cutaneous Lupus Erythematosus
Clin Exp Dermatol. 2022. Epub ahead of print doi:10.1111/ced.15335
First report of multiple cases of successful Cutaneous Lupus Erythematosus (CLE) treatment in active smokers with anifrolumab.
July 2022
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial
Jourde-Chiche N, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222435.
Non-inferiority of maintenance immunosuppressive therapy (IST) discontinuation after 2‒3 years was not demonstrated for renal relapse, in proliferative lupus nephritis (LN).
Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
Dörner T, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222335.
Phase II study results suggest that baricitinib 4 mg downregulates key cytokines that are upregulated in patients with SLE.
June 2022
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685
Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.